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Summary Attempts have been made by a number of methods to eliminate minimal residual disease from
bone marrow to be reinfused in autologous transplantation. In this paper we describe a conjugate containing
a monoclonal antibody, named 8A, recognising a plasma cell-associated antigen, and momordin, a ribosome-
inactivating protein similar to the ricin A-chain. This immunotoxin is active on target cell lines and on
neoplastic plasma cells, while myeloid progenitors are fairly resistant. The conjugate is shown to be acceptable
for ex vivo purging in autologous bone marrow transplantation in multiple myeloma patients.
A complete remission in multiple myeloma patients can
rarely be achieved with conventional chemotherapy. High
dose regimens of chemo- and radiotherapy followed by
allogeneic bone marrow transplantation succeeded in in-
ducing long lasting complete remissions even in patients with
massive bone marrow infiltration and/or drug resistance
(Tura et al., 1986; Garthon et al., 1987). However, only a
few patients may be treated with this protocol, mainly
because of lack of compatible donors and because of
advanced age. Autologous bone marrow transplantation has
been proposed as a possible alternative approach to multiple
myeloma therapy (Barlogie et al., 1986, 1987). The risk of
relapses due to the infiltration by neoplastic cells of the
autotransfused bone marrow explant is evidently a major
problem with this therapeutic protocol. The 'ex vivo purging'
of the bone marrow before the infusion could be a means of
reducing this risk. A number of clinical experiences have
already been reported in the field of bone marrow purging.
The removal of the residual malignant cells has generally
been attempted by complement-mediated cell lysis utilising
specific monoclonal antibodies (see for example Hale et al.,
1985) or with immunotoxins (reviewed by Blackey et al.,
1988). The plant ribosome-inactivating proteins (RIPs;
reviewed in Barbieri & Stirpe, 1982; Jimenez & Vazquez,
1985; Roberts & Selitrennikoff, 1986; Stirpe & Barbieri,
1986) have already been used to construct immunotoxins for
purging by several authors (Ramakrishnan & Houston, 1984;
Colombatti & Bron, 1985; Uckun et al., 1985; Vitetta &
Uhr, 1985, to quote some). These proteins are N-glycosidases
that hydrolitically cleave the N-glycosidic bond of A4324 of
28 S RNA (Endo et al., 1987; Stirpe et al., 1988) thus
blocking protein synthesis. The majority of immunotoxins
have been constructed utilising as toxic moiety the A-chain
of the ribosome-inactivating protein type 2 ricin. We think
that single-chain ribosome-inactivating proteins type 1 offer
several advantages over ricin A-chain (among which are
higher stability, easier handling and sometimes greater
efficiency). Several proteins of the latter group have already
been utilised to prepare immunotoxins (Blackey et al., 1987)
and recently promising results have been obtained in an
experimental model with the relatively less toxic ribosome-
inactivating proteins from Cucurbitaceae momordin and
bryodin (Stirpe et al., 1988). In this study we d1uate a new
immunoconjugate made with the anti-plasmaw cell mono-
clonal antibody 8A (Tazzari et al., 1987) and the ribosome-
inactivating protein momordin as a possible agent for bone
marrow purging in multiple myeloma.
Materials and methods
Monoclonal antibody
The characterisation of the 8A MoAb has been described
elsewhere (Tazzari et al., 1987). This antibody recognises
cells of the B-cell lineage from the terminal deoxynucleotidyl
transferase elements to plasma cells and subsets of mature
myeloid cells (Lemoli et al., 1988).
To prepare the antibody the hybridoma, growing in
complete RPMI 1640 (Biochrom) with 10% fetal calf serum
(Biochrom), glutamine, penicillin and streptomycin (Flow),
was injected (5 x 106 cells) in pristane-treated syngeneic
Balb/C mice. The ascitic fluid was collected and proteins
were fractionated by precipitation with 50% ammonium
sulphate. After dialysis against phosphate buffered saline
(PBS, 140mM NaCl containing 5mM sodium phosphate,
pH7.4) or TRIS/HCl buffer (10mM, pH7.5) IgG were
purified either by affinity chromatography on protein A, or
by conventional ion exchange chromatography on QAE-
Sepharose Fast Flow.
Preparation of conjugate
Momordin, prepared as described by Barbieri et al. (1987),
was freeze dried and stored at -20°C. The 8A-momordin
immunotoxin and the irrelevant bovine IgG-momordin
immunotoxin were prepared by linking the RIP to antibodies
with 2-iminothiolane, essentially as described by Stirpe et al.
(1988). The activity of the conjugated momordin was tested
on a lysate of rabbit reticulocytes after reduction with 50mM
dithiothreitol as described in a following paragraph. The
reactivity of the conjugated immunoglobulin was checked by
immunofluorescence, mixing 104u1 of the concentrated conju-
gate with 1 x 106 U266 or RAJI cells for 20min at room
temperature and subsequently with a FITC-conjugated goat
anti-mouse Ig (Becton Dickinson). Scoring was made by
means of a FacStar equipment (Becton Dickinson).
Cell lines
The Raji cell line (EBV infected, derived from a Burkitt
lymphoma) and the U266 cell line (derived from a human
multiple myeloma) were maintained in exponential growth
conditions in complete RPMI 1640 medium. Both RAJI and
U266 cell lines are recognised by the 8A MoAb. The cells
were harvested, checked for viability with ethidium bromide
and used at a concentration of 105ml-1.
Cell-free protein synthesis
Protein synthesis was measured with a rabbit reticulocyte
lysate as described previously (Stirpe et al., 1987). Reaction
mixtures contained in a final volume of 62.5pl: 10mM Tris/
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HCI buffer. pH 7.4, 100 mm ammonium acetate, mm ATP,
0.2 mM GTP, 15 mM phosphocreatine, 3 ,ug of creatine
kinase, 0.05 mM aminoacids (minus lcucinc), 89nCi of 1._I4C-
leucine, and 25pd of a rabbit reticulocyte lysate. Incubation
was at 28 'C for 5 min. The immunotoxin was reduced at
37 C for I h in the presence of 0.05 M dithiotreitol before
testing.
Inhibition of cell protein synthesis
Samples (900jul) of cell suspension were seeded in Falcon
tubes (Sterilin) and supplemented with 100 ll of complete
RPMI 1640 or of appropriately diluted solutions of momor-
din or immunotoxins. After incubation for 2h at 37°C in a
5% CO2/95% air atmosphere and centrifugation at 700g for
Omin, 900pl of the medium were substituted with an equal
volume of normal complete medium to eliminate the excess
of toxin or immunotoxin. After 48 h incubation the cells
were centrifuged as described and 900p1 of the medium were
substituted with an equal volume of leucine-free, serum-free
RPMI 1640 (Eurobio) containing 0.5pCi of L-3H-leucine
(Amersham). After incubation for 2h, the samples were
transferred onto filter paper disks by means of a Skatron
equipment (Flow), and counted with a scintillation P-counter
with Instagel scintillation liquid (Packard). Each experiment
was in duplicate.
Cell cloning inhibition
Samples (900,ul) of a cell suspension from every cell line
containing 1.1 x 106 cells ml-l were incubated as above with
100 4ul of complete RPMI 1640 alone or with a solution of
momordin, 8A-momordin conjugate or an irrelevant conju-
gate containing bovine-IgG and momordin (for the Raji cell
line only). The cell concentration was chosen after prelim-
inary experiments which demonstrated a higher sensitivity of
the method in these conditions. After incubation for 2h at
37°C the cells were washed, resuspended in 1 ml of complete
RPMI 1640 and 1,000 cells were seeded in a Petri dish
35 x 10mm (Nunc) in 1 ml of medium consisting of 850p1 of
complete RPMI 1640 and pl of normal human plasma
collected with 3.8% Na-citrate. Forty p1 of a 55mgml-1
CaCl solution was added to obtain clotting of the medium
(Bontadini et al., 1988). The dishes were then incubated at
37°C in a water-saturated 95% air/5% CO2 atmosphere until
clones of 8-32 cells could be scored in the control dishes
(usually 3-6 days for RAJI cell line, 6-10 days for U266).
All experiments were performed three times with three dishes
per point.
CFU-GM colony assay
Samples of heparinised bone marrow obtained from the
posterior iliac crest of healthy donors were separated on a
Ficoll-Hypaque gradient (Lymphoprep, Nyegaard) for
30min at 400g. The low density ('<1.077grml-1) fraction
was collected, washed twice with phosphate-buffered solution
(PBS) and the cells were counted and checked for viability
by means of trypan blue-dye exclusion.
The cells were incubated for 2h with the appropriate
amounts of momordin and immunotoxin and washed with
PBS by centrifugation at 600g for 5min. The cells were then
resuspended in 2.5ml of Dulbecco's minimal essential
medium (Gibco) supplemented with 0.9% methylcellulose,
20% FCS (Flow) and 10% PHA conditioned medium
(supernatant obtained from a 7 day culture of human
mononuclear fraction stimulated with 0 ugml phytd-
haemagglutinin, used as source of colony stimulating
activity) (Iscove et al., 1971). Cells were plated in Petri
dishes (35 x 1Omm) to a final concentration of 2 x 105ml-
and were incubated at 37°C in a fully humidified atmosphere
with 95% air/5% CO2. Colonies (>50 cells) and clusters
(20-50 cells) were scored at 7th and 14th day of culture.
Experiments were performed three times with three dishes
per point.
Bone marrow purging
A similar series of experiments were performed on 19
samples of bone marrow obtained from patients affected by
multiple myeloma, after informed consent. The mononuclear
cells, obtained as described above, were incubated for 2h
with complete RPMI 1640 or 10-8 M of 8A-momordin conju-
gate, washed and divided into three fractions. The first
fraction was immediately seeded for CFU-GM rescue as
described above. The second one, after washing, was allowed
to stand in liquid culture with complete RPMI 1640 for 72h,
to evaluate the purging of plasma cells. In fact, an interval
of 2-3 days is needed to see the cell death caused by
immunotoxin, in contrast to the complement-mediated lysis
which occurs immediately. After this time the samples were
tested for viability with ethidium bromide, diluted 1:4 with
saline and layered onto Ficoll-Hypaque to eliminate cellular
debris and dead cells which in control samples were always
<10%. The cells were then collected, counted and cytospin
preparation were obtained. The slides, fixed for 30min
in cold (4°C) methanol, were rehydrated, and incubated
for 30min with a tetra-methyl-rhodamine-isothiocyanate
(TRITC) conjugate goat anti-human Ig. The preparations
were then washed overnight with PBS and mounted with
PBS-glycerol (1:1). For the evaluation of residual plasma
cells, approximately 1,000 cells were counted. The last
fraction was cultured in complete RPMI 1640 for 72h for the
study of plasma cell precursors identified as B-cell expresspg
a cytoplasmatic spot of Ig and with high nuclear incorpora-
tion of 2-bromodeoxyuridine (Lokhorst et al., 1987; Tassi et
al., 1988). Briefly, after the 72h incubation, 0.3mgml-1 of
2-bromodeoxyuridine was added in the medium. Cytospins
were obtained after 30min, were fixed for 10min with
ethanol and acetic acid (3:1) and incubated sequentially with
anti-bromodeoxyuridine TRITC-MoAb and with goat FITC-
conjugated anti-human immunoglobulin serum. The slides,
after overnight washing in PBS, were mounted in PBS-
glycerol and a mean of 2,000 cells were counted using a
fluorescence microscope.
Results
Chemical characteristics of the conjugate
The immunotoxin utilised throughout the present experi-
ments was the 'low molecular weight' component of the
mixture obtained upon conjugation (Thorpe et al., 1985).
Each molecule of conjugate contained only 1 mol of anti-
body and a maximum of 2mol of momordin. The character-
istics of the immunotoxin are described in Table I. In
particular the activity of the conjugated momordin (IC50
6.8 x 10-11M) is very similar to that of the native molecule
(IC50 6.2xIOI0M).
Killing of target cell lines
The conjugate inhibited protein synthesis by target cell lines
with high specificity. Toxicity of momordin for cell lines
bearing the 8A-related antigen (U266 and Raji) increased
over 1,000-fold (Table II) upon conjugation with the 8A
Table I Chemical characteristics of the conjugate
containing the 8A-monoclonal antibody and the
ribosome-inactivating protein momordin
8A MoAb: mouse IgGI
RIP: momordin, from Momordica charantia
Linking agent: 2-iminothiolane
Momordin content: 3.07 x 10-6M
8A-MoAb content: 3.09 x 10-6 M
Molar ratio, momordin/antibody: 0.99
IC a: 6.8x10 11M 50
aConcentration (expressed as momordin content)
giving 50% inhibition of protein synthesis in the
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Table II Inhibition of protein synthesis by 8A-momordin immunotoxin
Momordin concentration (moo
Cell line Addition None 10-7 10-8 J0-9 10-10 LD50
U266 momordin 16,247+1,089 15,029+ 988 15,907+1,126 13,907+ 968 n.d. no effect 8A-momordin 16,247± 1,089 5,887+ 318 7,152+ 414 8,446+ 486 16,409+1,008 1 x 10-9M
RAJI momordin 30,569+2,316 18,983+1,066 29,599+1,664 30,871+1,886 n.d. 5x 10-6M 8A-momordin 30,569+2,316 2,621+ 206 4,666+ 322 16,691+ 818 34,888+1,924 2.8 x 10-9M
Target cells were U266 (derived from multiple myeloma) and Raji (derived from Burkitt lymphoma). 14C-Leucine incorporated (d.p.m.). Mean of triplicate counts.
antibody, while no cytotoxicity was observed with a mixture
of unconjugated 8A and momordin and with an immuno-
toxin made with an irrelevant antibody (bovine-IgG) (data
not shown).
A better demonstration of the efficacy of immunotoxin
was obtained with cloning efficiency inhibition tests. With
this method a higher sensitivity of U266 cell line to the
cytotoxic effect of the immunotoxin was confirmed. A
0
(.) c;
0)
0)
0 .2
r-
a
Momordin (mol 1-1)
Figure 1 Inhibition of colony growth on cell lines. The cloning
efficiency was tested in the presence of free (-----) or conjugated
momordin ( ). a, U266 cells (derived from multiple mye-
loma); b, Raji cells (derived from Burkitt lymphoma). Control
values were 323+27 and 129+14 for Raji and U266 cell lines
respectively.
complete elimination of U266 clones was reached at a
concentration of 10-8M (Figure la), whereas the Raji cells
were not completely killed at a 10-fold higher concentration
(Figure lb). This could be due to higher expression of the
antigen recognised by 8A MoAb on U266 cell line as it
appears by cytofluorimetric analysis (Tazzari et al., 1987).
Moreover, with this test the LD50 were 5.8xIO-10M and
2.2 x 10-10 M for U266 and Raji respectively, lower than the
IC50 for protein synthesis, probably due to the higher
sensitivity of the cloning method.
No cytotoxicity was observed in a series of experiments
run with an irrelevant immunotoxin consisting of momordin
linked to bovine-IgG, and with 8A MoAb alone or mixed
with free momordin (data not shown).
Rescue ofmyeloidprogenitors
Cells harvested from human normal bone marrow were
treated in the same conditions as cell lines to determine the
aspecific toxicity of the conjugate. The rescue of CFU-GM
ranged from 32% to 100% depending on the momordin
concentration (Table III).
Bone marrow purging
In a series of bone marrow samples obtained from multiple
myeloma patients, a sufficient number of CFU-GM was
retained after incubation of the cell suspension with a single
concentration of 10-8M immunotoxin, expressed as momor-
din content. The elimination of neoplastic plasma cells was
of 88-99% after 72h (Table IV) and the residual plasma
cells were morphologically damaged.
The analysis of the proliferating B-cell compartment,
taken as an indication of the plasma cell precursors pool,
showed a complete disappearance of the S-phase B-cells in
2/3 of the marrows and a three log reduction in the other
cases.
Discussion
In recent years, autologous bone marrow transplantation has
been used in a number of neoplastic diseases. The most
common application was in the consolidation phases of
patients affected by acute leukaemias or high grade non-
Hodgkin's lymphomas (Dicke & Spitzer, 1986). Recently, an
extension to multiple myeloma patients has been described
(Barlogie et al., 1986). However, the presence of neoplastic
Table III CFU-GM rescue after exposure of normal bone marrows to free momordin and 8A-momordin immunotoxin
Momordin 8A-momordin
Controls
Sample no. Score day (no. of colonies) 10-7M 10-8M 10-9M 10-7Ma JO-8Ma 10-9Ma
I 7th 601 +75 n.d. 89+5 98+2 n.d. 68+6 101+2
14th 430+53 n.d. 83+3 81+4 n.d. 58+3 93+4 2 7th 428+49 51+4 54+3 54+5 32+4 61+5 81+5
14th 133+18 87+6 86+4 98+3 42±3 121+7 83+6 3 7th 457+44 62+5 107+6 101+3 34+6 70+8 91+4
14th 367+37 56+4 79+6 73±5 37+4 46+5 61+5
Mean of triplicate counts +s.d. expressed as percentage of controls; aMolarity expressed as mormodin content.
^ AA 1
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Table IV Evaluation of CFU-GM rescue and plasma cell purging after exposure of multiple myeloma bone marrows to 10-8M
8A-momordin
CFU-GM % Plasma cells % PC precursors
Rescue Purging
Sample no. Before IT After IT % Before IT After IT % Before IT After IT
1 55+ 7a 7+ la (13) 22 0.2 +0.04 (98) 2.5 0
2 81 + 9 60+ 6 (74) 15 0.4 +0.05 (97) 1.8 0
3 132+12 61 + 5 (46) 25 1.1 +0.04 (95) 2.2 0.001
4 27+ 3 9+ 2 (33) 40 0.3 +0.02 (>99) 3.7 0
5 89+ 7 27+ 4 (30) 80 0.8 +0.03 (98) 5.3 0.0002
6 765+36 214+18 (28) 10 0.6 +0.05 (93) 0.1 0
7 646+41 65+ 8 (10) 60 3.3 +0.07 (94) 4.4 0.001
8 177 +12 94+ 5 (53) 20 0.1 +0.03 (>99) 4.2 0
9 39+ 4 31+ 3 (79) 25 0.2 +0.02 (>99) 1.9 0
10 238+ 14 124+ 9 (52) 60 1.6 +0.04 (97) 7.8 0
11 80+ 8 60+ 5 (75) 30 0.5 +0.04 (98) 3.6 0
12 48+ 6 20+ 3 (42) 15 0.1 +0.05 (98) 0.8 0.001
13 138+ 11 99+ 7 (72) 65 2.9 +0.02 (95) 1.1 0.002
14 63+ 8 43+ 5 (68) 20 1.1 +0.04 (94) 0.9 0
15 109+ 8 90+ 9 (83) 60 1.3 +0.08 (97) 2.6 0
16 50+ 4 20+ 4 (40) 35 1.1 +0.02 (96) 6.1 0
17 74+ 6 18+ 3 (24) 10 0.02+0.005 (>99) 1.0 0
18 128+ 9 72+ 8 (56) 30 0.4 +0.08 (88) 2.1 0.0003
19 159+ 14 52+ 7 (33) 20 0.06+0.004 (>99) 2.8 0
CFU-GM values are mean +s.d. of triplicate counts at 14th day of culture. Plasma cells and PC precursors were evaluated after
treatment with immunotoxin (IT) for 2h, washing and liquid culture for 72h. Almost 1,000 cells were counted. dC)lonics per
2.5 x 105 plated cells.
cells in the reinfused marrow could be responsible for the
high number of relapses. In fact, it was estimated that
1-2 x 103 clonogenic neoplastic cells are usually reinfused to
patients affected by acute leukaemias who previously
achieved complete remission (Hagenbeek & Lowenberg,
1986). Also, in multiple myeloma patients receiving non-
purged bone marrow a significant number of relapses was
observed (Barlogie et al., 1987).
The complement-mediated cell lysis used to eliminate
neoplastic cells with specific MoAbs poses a few problems.
The cell treatment is lengthy, bears the risk of loss of normal
cells and the efficiency of complement (usually from rabbits)
as well as its aspecific toxicity varies from batch to batch.
Moreover, the cell lysis is antigen density dependent and
probably a number of membrane holes could be repaired by
the target cells (Goldmacher et al., 1985; Prentice et al.,
1982).
The immunotoxins made with ricin A-chain and other
ribosome-inactivating proteins should remove some of the
disadvantages described above, due to the high potency of
the toxic moieties. The previous experience with anti-plasma
cell-saporin immunotoxins (Barbieri et al., 1988) showed that
efficient killing agents to be used for bone marrow purging
could indeed be prepared with the 8A antibody and a
ribosome-inactivating protein type 1. However, the toxicity
of saporin 6 to mice increased dramatically after conjugation
(Stirpe et al., 1987; Barbieri et al., unpublished results), the
main lesion being hepatic necrosis. Immunotoxins made with
momordin are 50-fold less toxic to mice (LD50 4mgkg-1)
than those containing saporin (LD50 70Mgkg- 1) and doses
up to 100Mg kg- 1 did not cause any apparent hepatic lesion.
This prompted us to prepare an immunotoxin with momor-
din. The concentration of conjugated momordin used for the
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